This means that passive immunization with tau antibodies is really a viable therapeutic focus on and the CSF standard of p-tau262/356 or with the microtubule binding area (MTBD) can serve as a handy biomarker of tau pathology to observe tau therapeutics in scientific trials.They demonstrated this relationship with both pathological specimens and by